Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...

Biogen’s gamble on multiple sclerosis drug opicinumab looks increasingly ... after patients switched from reference anti-TNF products to a biosimilar, which could help assuage the fears of ...

Biogen expects revenue to decline by a "mid-single digit" percentage in 2025 compared with 2024, as sales of its multiple sclerosis products fall. That portion of the business has declined for ...

On a call with analysts, Chief Executive Chris Viehbacher said the four products launched ... are a key part of Biogen's strategy to combat the increased competition in the MS space.

Biogen Inc. has disclosed uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists with improved brain penetration reported to be useful for the treatment of multiple sclerosis.

Biogen's MS portfolio is under pressure from newer ... and Plegridy improves convenience to twice-monthly injections, but these products are less effective than newer options like Ocrevus.

Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers ...